2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Torvutatug samrotecan: new trials by email Literature Review of Torvutatug samrotecan trials Research Report on Torvutatug samrotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer | Phase 3 | Recruiting | AstraZeneca | 600 | 2026-09-24 | 2026-10-16 |
| Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 950 | 2026-09-16 | 2026-11-06 |
Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (1)
AstraZeneca (2)
Australia (2) · Brazil (2) · Canada (2) · China (2) · Germany (2) · India (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · Taiwan (2) · Thailand (2) · United States (2) · Argentina (1) · Bulgaria (1)